Neurosense Therapeutics Ltd(NRSN)

POST6.950.000.00%19:37 EDT

6.95-0.45-6.08%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Press Release: NeuroSense Provides Business Update and Progress for the First Half of 2026
  Dow Jones · 09-26 04:30
  Press Release: NeuroSense Provides Business Update and Progress for the First Half of 2026
- NASDAQ Trade Halt Continues Reason not Available at 06:55 Am
  Reuters · 09-14
  NASDAQ Trade Halt Continues Reason not Available at 06:55 Am
- Neurosense Therapeutics Ltd trading halted, news pending
  TIPRANKS · 09-12
  Neurosense Therapeutics Ltd trading halted, news pending
- NASDAQ Trade Halt Halt News Pending at 07:50 Pm
  Reuters · 09-12
  NASDAQ Trade Halt Halt News Pending at 07:50 Pm
- NeuroSense Therapeutics to Present at H.C. Wainwright Global Investment Conference
  Reuters · 09-10
  NeuroSense Therapeutics to Present at H.C. Wainwright Global Investment Conference
- Neurosense Therapeutics Ltd: to Effect Reverse Share Split of Co’s Ordinary Shares at Ratio of 1-for-20
  THOMSON REUTERS · 09-10
  Neurosense Therapeutics Ltd: to Effect Reverse Share Split of Co’s Ordinary Shares at Ratio of 1-for-20
- NeuroSense Therapeutics Effects 1-for-20 Reverse Stock Split on Sept. 14, 2026
  Reuters · 09-10
  NeuroSense Therapeutics Effects 1-for-20 Reverse Stock Split on Sept. 14, 2026
- NeuroSense Therapeutics Initiated at Buy by HC Wainwright & Co.
  Dow Jones · 09-03
  NeuroSense Therapeutics Initiated at Buy by HC Wainwright & Co.
- Neurosense Therapeutics Ltd. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $8
  THOMSON REUTERS · 09-03
  Neurosense Therapeutics Ltd. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $8
- NeuroSense announces redesigned development plan for PrimeC
  TIPRANKS · 08-31
  NeuroSense announces redesigned development plan for PrimeC
- NeuroSense Targets Faster, Lower-Cost ALS Approval Path for PrimeC Under Revamped Development Plan
  Reuters · 08-31
  NeuroSense Targets Faster, Lower-Cost ALS Approval Path for PrimeC Under Revamped Development Plan
- NeuroSense Plans Head-to-Head PrimeC Trial Versus Mitsubishi Tanabe’s Edaravone in ALS
  Reuters · 08-31
  NeuroSense Plans Head-to-Head PrimeC Trial Versus Mitsubishi Tanabe’s Edaravone in ALS
- Neurosense Unveils Accelerated, Capital-Efficient Strategy to Advance Primec Toward Potential Approval in ALS
  THOMSON REUTERS · 08-31
  Neurosense Unveils Accelerated, Capital-Efficient Strategy to Advance Primec Toward Potential Approval in ALS
- NeuroSense Therapeutics Shareholders Authorized Board to Pursue Reverse Stock Split Range 1-for-4 to 1-for-40
  Reuters · 08-28
  NeuroSense Therapeutics Shareholders Authorized Board to Pursue Reverse Stock Split Range 1-for-4 to 1-for-40
- NeuroSense Announces Shareholder Letter Availability
  Reuters · 08-13
  NeuroSense Announces Shareholder Letter Availability
- NeuroSense Targets December 2026 Canada Filing for PrimeC ALS Drug Amid Phase 3 Paragon Preparations
  Reuters · 08-13
  NeuroSense Targets December 2026 Canada Filing for PrimeC ALS Drug Amid Phase 3 Paragon Preparations
- Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN) and Brookdale Senior Living (BKD)
  TIPRANKS · 08-11
  Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN) and Brookdale Senior Living (BKD)
- NeuroSense sees December 2026 as filing date for NDS for PrimeC
  TIPRANKS · 08-06
  NeuroSense sees December 2026 as filing date for NDS for PrimeC
- NeuroSense Therapeutics Announces Special Shareholder Meeting
  Reuters · 08-01
  NeuroSense Therapeutics Announces Special Shareholder Meeting
- NeuroSense Amends JonesTrading Equity Distribution Agreement for up to $3.79 Million Share Sales
  Reuters · 08-01
  NeuroSense Amends JonesTrading Equity Distribution Agreement for up to $3.79 Million Share Sales
Company Profile
Company Name
Neurosense Therapeutics Ltd
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.neurosense-tx.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
- 03-31
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2025-11-25
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2025-08-15
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 2025-04-07
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2025-01-16
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2025-01-06
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-12-13
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-12-09
  Beneficial Ownership Change
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
- 2024-11-22
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-11-19
  Public Prospectus
  Form F-1 - Registration statement for certain foreign private issuers
  Form F-1 - Registration statement for certain foreign private issuers
- 2024-05-21
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-05-20
  [Amend]Public Prospectus
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
  Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
- 2024-05-10
  Public Prospectus
  Form F-1 - Registration statement for certain foreign private issuers
  Form F-1 - Registration statement for certain foreign private issuers
- 2024-04-04
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2024-02-13
  Beneficial Ownership Change
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

1D
5D
Day
Week
Month

Loading ...

High

7.18

Open

7.18

Volume%

0.72

Low

6.73

7.40

T/O Rate

0.67%

To The Moon

Neurosense Therapeutics Ltd(NRSN)

Company Profile

Most Discussed